Aceragen (ACGN) Form 3 IDERA PHARMACEUTICALS / John J. Kirby ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Kirby John J.

(Last) (First) (Middle)

C/O IDERA PHARMACEUTICALS, INC.

505 EAGLEVIEW BLVD., SUITE 212

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/31/2018

3. Issuer Name and Ticker or Trading Symbol
IDERA PHARMACEUTICALS, INC. [ IDRA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
V.P. of Finance, PFO & PAO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,259(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)(3)	11/02/2025	Common Stock	18,750	24.88	D
Stock Option (Right to Buy)	(2)(4)	01/06/2026	Common Stock	11,249	23.04	D
Stock Option (Right to Buy)	(2)(5)	01/04/2027	Common Stock	12,499	12.72	D
Stock Option (Right to Buy)	(2)(6)	01/03/2028	Common Stock	16,874	17.92	D
Stock Option (Right to Buy)	(2)(7)	08/13/2028	Common Stock	10,000	7.39	D

Explanation of Responses:

1. Includes 1,809 shares purchased through the Company's 1995 and 2017 Employee Stock Purchase Plans.

2. Option vests over a four-year period commencing on the grant date. 25% vests on the first anniversary date of grant with the balance vesting in equal quarterly installments over the remaining three years of the four-year vesting period.

3. Grant date 11/2/15.

4. Grant date 1/6/16.

5. Grant date 1/4/17.

6. Grant date 1/3/18.

7. Grant date 8/13/18.

	/s/ John J. Kirby	11/02/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.